{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:29:04Z","timestamp":1790458144417,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T00:00:00Z","timestamp":1428278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The safety and efficacy of yttrium 90 (<jats:sup>90<\/jats:sup>Y) therapy for unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) requires further evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A prospective, single\u2010center safety and feasibility study recruited patients with unresectable (Barcelona Clinic Liver Cancer stage C) infiltrative HCC with PVT. Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0. Overall survival (OS) and time to progression (TTP) were measured from the first <jats:sup>90<\/jats:sup>Y therapy. Survival analysis was performed with Kaplan\u2010Meier estimation. Prognostic factors were tested with a log\u2010rank test and Cox proportional regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Overall, 45 patients were recruited, and 30 patients who met the study's inclusion criteria underwent glass\u2010based <jats:sup>90<\/jats:sup>Y therapy. Four patients (13%) had transient hepatobiliary toxicity (grade\u2009\u2265\u20092). Ten patients (33%) had related emergency department visits, with 5 patients (17%) requiring short\u2010term hospitalization. No radiation pneumonitis, gastrointestinal ulceration, or procedure\u2010related mortality occurred. The median OS was 13 months (95% confidence interval, 4.4\u201022 months) with a TTP of 9 months (95% confidence interval, 6.2\u201013.1 months). Absence of ascites, an international normalized ratio\u2009&lt;\u20091.2, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, Child\u2010Pugh class A, a macroaggregated albumin lung shunt fraction (LSF)\u2009&lt;\u200910%, and no hepatobiliary toxicity were significant predictors of prolonged OS according to a univariate analysis (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). A multivariate analysis found an ECOG performance status of 0, Child\u2010Pugh class A, an LSF\u2009&lt;\u200910%, and lack of transient hepatobiliary toxicity (grade\u2009\u2265\u20092) to be independent predictors of prolonged OS (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). An ECOG performance status of 0, Child\u2010Pugh class A, and an LSF\u2009&lt;\u200910% were also predictors of prolonged TTP according to the multivariate analysis (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In patients with unresectable infiltrative HCC and PVT, <jats:sup>90<\/jats:sup>Y therapy appears to be a safe and viable therapy. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:2164\u20132174.<\/jats:bold> \u00a9 <jats:italic>2015 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29275","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T10:29:53Z","timestamp":1428316193000},"page":"2164-2174","source":"Crossref","is-referenced-by-count":57,"title":["Open\u2010label prospective study of the safety and efficacy of glass\u2010based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis"],"prefix":"10.1002","volume":"121","author":[{"given":"Nima","family":"Kokabi","sequence":"first","affiliation":[{"name":"Division of Interventional Radiology and Image Guided Medicine, Department of Radiology Emory University School of Medicine Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Camacho","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology and Image Guided Medicine, Department of Radiology Emory University School of Medicine Atlanta Georgia"},{"name":"Division of Abdominal Imaging, Department of Radiology Emory University School of Medicine Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Xing","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology and Image Guided Medicine, Department of Radiology Emory University School of Medicine Atlanta Georgia"},{"name":"Division of Interventional Radiology, Department of Radiology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel F.","family":"El\u2010Rayes","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine Emory University School of Medicine Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Spivey","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine Emory University School of Medicine Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Knechtle","sequence":"additional","affiliation":[{"name":"Duke Transplant Center, DUMC 3512 Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology and Image Guided Medicine, Department of Radiology Emory University School of Medicine Atlanta Georgia"},{"name":"Division of Interventional Radiology, Department of Radiology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania"},{"name":"Division of Medical Oncology, Department of Medicine Emory University School of Medicine Atlanta Georgia"},{"name":"Cancer Therapeutics Program University of Pittsburgh Cancer Institute Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7753"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.011"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3210"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-011-1614-7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.10336"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.137.6.653"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-012-1364-2"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(07)61790-4"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23944"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26014"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24451"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.006"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2010.04.012"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21980"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2013.11.007"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2010.10.029"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-013-0709-9"},{"key":"e_1_2_7_23_1","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201006\u201014_QuickReference_5x7.pdf. Accessed February 11 2014."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.10.005"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/815105"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29275","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T22:08:32Z","timestamp":1760306912000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,6]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/cncr.29275"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29275","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,6]]}}}